Accelerating Progress in Human Health and Scientific Research
Parse Biosciences is a Seattle-based company with the mission of accelerating progress in human health and scientific research.
The people of Parse are curious, collaborative, and driven by purpose.
News
Upcoming Events
Advances in Genome Biology and Technology (AGBT)
Feb 6 - Feb 9
Parse Biosciences is proud to be a Bronze Sponsor at AGBT’s flagship event for bringing together global leaders, researchers, and innovators. If you are attending, please visit us in suite 215.
More Information
NextGen Omics US
Mar 30 - Mar 31
The NextGen Omics US: In-Person event is an exclusive collaborative environment, welcoming over 300 attendees from international Pharma, Biotech & Academic institutions. Parse Biosciences team members will discuss our Evercode single cell RNA sequencing platform in a Day One presentation.
More Information
Advances in Genome Biology and Technology (AGBT)
Parse Biosciences is proud to be a Bronze Sponsor at AGBT’s flagship event for bringing together global leaders, researchers, and innovators. If you are attending, please visit us in suite 215.
NextGen Omics US
The NextGen Omics US: In-Person event is an exclusive collaborative environment, welcoming over 300 attendees from international Pharma, Biotech & Academic institutions. Parse Biosciences team members will discuss our Evercode single cell RNA sequencing platform in a Day One presentation.
Leadership
Alex Rosenberg, Ph.D.
Alex cofounded Parse Biosciences and leads the organization as its Chief Executive Officer. Alex is an experienced leader and technologist with a track record of pushing innovation in next-generation sequencing, machine learning, and predictive models of biology. As a Commercialization Fellow at the University of Washington, Alex co-invented the single cell technology that inspired Parse’s foundational Evercode™ platform. Alex is an active technical leader and inventor with multiple publications in high-profile journals such as Cell and Science and several patents.
Alex received a Ph.D. in Electrical Engineering from the University of Washington and BSE in Electrical Engineering from the University of Michigan.
Charlie Roco, Ph.D.
Charlie cofounded Parse Biosciences and leads as its Chief Technology Officer. Charlie is passionate about biology-based technology development, with over a decade of driving innovation in the field. Prior to Parse, he was at the University of Washington where he received several fellowships from the NIH and Fred Hutch Cancer Research Center. This work generated high-profile publications in Science and informed the core technology of Parse Biosciences. Previously, Charlie contributed to innovations in drug delivery and microscopy at the Wyss Institute at Harvard and the University of Pennsylvania.
Charlie received a Ph.D. in Bioengineering from the University of Washington and BSE in Biological Systems Engineering from Virginia Tech.
Britton Russell
Britton serves as Chief Financial Officer at Parse Biosciences. Having worked in both emerging growth companies as well as large multinational organizations, Britton provides experienced financial leadership. He previously worked in Finance leadership positions at Genapsys, a DNA sequencing company; ArcherDX, a genomic analysis company; and later Invitae, after it acquired ArcherDX in October 2020. Prior, Britton held a diverse range of corporate finance roles with increasing responsibility at AstraZeneca, Genentech/Roche, and Royal Dutch Shell.
Britton holds an MBA from Rice University, a BS in Finance, and a BA in Business and Sustainability from Arizona State University.
